Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2007 5
2008 8
2009 3
2010 1
2011 4
2012 6
2013 4
2014 1
2015 2
2016 12
2017 6
2018 8
2019 5
2020 5
2021 7
2022 14
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C. Becker PS, et al. Among authors: ullrich e. Cancer Immunol Immunother. 2016 Apr;65(4):477-84. doi: 10.1007/s00262-016-1792-y. Epub 2016 Jan 25. Cancer Immunol Immunother. 2016. PMID: 26810567 Free PMC article. Review.
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Albinger N, et al. Among authors: ullrich e. Blood Cancer J. 2022 Apr 13;12(4):61. doi: 10.1038/s41408-022-00660-2. Blood Cancer J. 2022. PMID: 35418180 Free PMC article.
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.
Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. Brand A, et al. Among authors: ullrich e. Cell Metab. 2016 Nov 8;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011. Epub 2016 Sep 15. Cell Metab. 2016. PMID: 27641098 Free article.
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.
Akahoshi Y, Spyrou N, Hogan WJ, Ayuk F, DeFilipp Z, Weber D, Choe HK, Hexner EO, Rösler W, Etra AM, Sandhu K, Yanik GA, Chanswangphuwana C, Kitko CL, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp SA, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine JE, Ferrara JLM, Chen YB. Akahoshi Y, et al. Among authors: ullrich e. Blood Adv. 2023 Aug 22;7(16):4479-4491. doi: 10.1182/bloodadvances.2023009885. Blood Adv. 2023. PMID: 37315175 Free PMC article.
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: ullrich e. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Unleashing the power of NK cells in anticancer immunotherapy.
Vogler M, Shanmugalingam S, Särchen V, Reindl LM, Grèze V, Buchinger L, Kühn M, Ullrich E. Vogler M, et al. Among authors: ullrich e. J Mol Med (Berl). 2022 Mar;100(3):337-349. doi: 10.1007/s00109-021-02120-z. Epub 2021 Aug 9. J Mol Med (Berl). 2022. PMID: 34374809 Free PMC article. Review.
101 results